Stain-guided parotidectomy: a preliminary report of our experience. January to June 2024

Journal: Advances in Medicine and Engineering Interdisciplinary Research DOI: 10.32629/ameir.v3i4.4854

Luis Fagúndez1, Jessica Salazar1, Aida Sánchez2, María Gabriela Sánchez1, Esteban Garriga1, José Núñez1

1. Hospital Oncology Service IVSS, Bolivarian Republic of Venezuela
2. "Dr. Carlos Arvelo" Military Hospital, Department of Otorhinolaryngology, Bolivarian Republic of Venezuela

Abstract

Objective: Evaluate the usefulness of stain- guided parotidectomy in patients with parotid tumors in the Head and Neck Services of the Hospital Oncology Social Security Service and the Otorhinolaryngologic Service of the "Dr. Carlos Arvelo" Military Hospital January to June 2024. Method: A descriptive, prospective study was conducted with a sample of 17 patients. Results: Age uniform distribution in the ranges 15-30, 31-45, 46-60 years with 5(29.4 %), 61-74 years with 2 (11.8 %). The female sex predominated with 14 (82.4 %) over the male sex 3 (17.6 %). Predominance of left parotid tumors 9 (52.9 %) vs. 8 (47.1 %) right. The predominant histological type was pleomorphic adenoma in 15 patients (88.2 %), carcinoma ex pleomorphic adenoma in 1 (5.9 %), and high-grade mucoepidermoid carcinoma in 1. Superficial parotidectomy as a surgical procedure predominated in 15 (88.2 %) patients and total parotidectomy with neck dissection in 2 (11.8 %). The complications observed included facial edema in 4 (23.5 %) patients, paresis in 3 (17.6%) reported as House Brackmann (HB) II, transient periatrial dysesthesia in 3 (17.6 %), and salivary fistula in 1 (5.9 %). Facial nerve identification and parenchymal staining were achieved in 17 patients (100.0 %). Conclusion: Treatment for salivary gland neoplasms should be individualized. In our experience, the integration of methylene blue as an intravital staining agent in parotid surgery has shown promising potential, with fewer sequelae in patients, which translates into adequate aesthetic, functional and oncological results.

Keywords

parotid; surgery; methylene blue; facial nerve; paresis

References

[1] Holsinger F, Bui D. Anatomy, function, and evaluation of salivary glands. En: Salivary Gland Disorders. Berlín:Springer Verlag; 2007.p.1-6.
[2] Córdova A, Cajas M, Crespo P, Pineda D. Características anatómicas y funcionales de la glándula parótida. una revisión de la literatura. Revista Odontología Activa. 2022;7(2):55-64.
[3] Rosa M, Lazarz D, Pękala J, Skinningsrud B, Lauritzen S, Solewski B, et al. The accessory parotid gland and its clinical significance. J Craniofac Surg. 2020;31(3):856-860.
[4] Velasco I, Salinas F, Aguilar L, Gallego A, Pastrián J, Fariña R, et al. Consideraciones anatómicas en la parotidectomía: revisión de la literatura a propósito de un caso. Int. J. Morphol. 2013;31(1):231-238.
[5] Cisternas M, Corrochano E, Saa M. Patología tumoral de las glándulas salivales. Libro virtual de formación en ORL SEORL. España; 138: 1-16. Disponible en: URL: https://www.studocu.com/cl/document/universidad-nacional-andres-bello/ecografia/148-patologia-tumoral-de-las-glandulas-salivares/99818048.
[6] Bravo G, Seymour C, Fernández L, Villanueva M, Stott C, Celedón C. Tumor híbrido parotídeo. Rev Otorrinolaringol Cir Cabeza Cuello. 2012;72(3):282-290.
[7] Maza J, Sánchez S, Herrero T, Benavente G, Ventura J, de Mingo E. Clasificación pronóstica de los tumores malignos de la glándula parótida. Rev Esp Cir Oral Maxilofac. 2016;38(1):11-16.
[8] Cohen EG, Patel SG, Lin O, Boyle JO, Kraus DH, Singh B, et al. Fine-needle aspiration biopsy of salivary gland lesions in a selected patient population. Arch Otolaryngol Head Neck Surg. 2004;130(6):773-778.
[9] Yáñez R, Loyola F, Maíz C, Cornejo J, Martínez R, Valenzuela M. Tratamiento quirúrgico de los tumores de parótida: experiencia de 10 años. Rev Chil Cir. 2014;66(3):245-250.
[10] Biel J, Sánchez G, Ignacio A, Escobar S, Martínez V. Tumores de la glándula parótida. Protocolos y Guías de Práctica Clínica en Cirugía Bucal. SECIB. 2005;50:693-708. Disponible en. URL: https://www.secomcyc.org/wp-content/uploads/2014/01/cap50.pdf.
[11] Witt R. The significance of the margin in parotid surgery for pleomorphic adenoma. Laryngoscope. 2002; 112(12):2141-2154.
[12] Coulson S, O'Dwyer N, Adams R, Croxson G. Expression of emotion and quality of life after facial nerve paralysis. Otol Neurotol. 2004;25(6):1014-1019.
[13] Guerrissi J, Amante M, Filippini A, Kosima S, Contino R. Cirugía De Los Tumores De La Glándula Parótida. Colombia: AMOLCA; 2007.p.104-116.
[14] Haubner F, Gassner H, Brawanski A, Schebesch K. Fluorescein sodium-guided surgery of parotid gland tumors as a technical advance. BMC Ear Nose Throat Disord. 2017;17:6.
[15] Mijares A, Núñez J, Suárez C, Acevedo L, Bracamonte A. Monitoreo intraoperatorio del nervio facial en cirugía de parótida. Rev Venez Oncol. 2021;33(4): 215-224.
[16] Sood A, Houlton J, Nguyen S, Gillespie MB. Facial nerve monitoring during parotidectomy: A systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2015;152(4):631-637.
[17] Callero H, Arrieta J. Evaluación y tratamiento asistido con tinción de la enfermedad quirúrgica de la parótida. An Orl Mex. 2006;51(3):121-128.
[18] Cheesman A. Intra-vital staining as an aid to parotid gland surgery. Clin Otolaryngol Allied Scie.1977;2(1):17-21.
[19] Rodríguez Y, Granado R, Fernández R, Martínez D, Morales D. Tumores de glándulas salivales. Experiencia de cinco años. Acta Med Centro. 2021;15(2) 229-239.
[20] Vaiman M, Jabarin B, Abuita OR. Methylene blue staining in the parotid surgery: Randomized trial, 144 patients. Am J Otolaryngol. 2016;3(7):22-26.
[21] Tapia M, Hernández T, Fredes F, Urra A, Compan A, Ortega P. Tumores de glándula parótida: experiencia quirúrgica Hospital Guillermo Grant Benavente. Rev Otorrinolaringol Cir Cabeza Cuello. 2018;78(4):385-391.
[22] Bauta M, Gómez R, Gómez O, Yadnil E. Caracterización clínica y anatomopatológica del adenoma pleomórfico de glándulas salivales. Univ Méd Pinareña. 2021;17(2): e519.
[23] Barragán W, Cueva J, Cedeño M, Regalado R, Villacrés D. Adenoma pleomorfo de parótida, manejo quirúrgico: a propósito de un caso. Revista Médica HJCA. 2020;12(1): 68-73.
[24] Aguirre A, Loreto M. Tumores de la parótida. Tratamiento quirúrgico. Rev. Chilena de Cirugía. 2004;56(1):51-56.
[25] Nahlieli O, Levy Y. Intravital staining with methylene blue as an aid to facial nerve identification in parotid gland surgery. J Oral Maxillofac Surg. 2001;59(3):355-356.
[26] Catania V, Gennari L. Valutazione dell'utilita della impregnazione del parenchima ghiandolare con blu di metilene nella chirurgia della parotide. Tumori. 1964;50:309-316.
[27] Subhash S, Bagchi U, Ethiraj S. The role of methylene blue in mitigating surgical morbidity in parotid surgery: A comprehensive review. Int Surg J. 2023;10(9):1562-1567.
[28] Seok J, Kim JH, Yoo JY, Lee BJ. Long-term quality of life after parotidectomy for benign parotid tumors. Laryngoscope. 2018;128(6):1351-1355.

Copyright © 2026 Luis Fagúndez, Jessica Salazar, Aida Sánchez, María Gabriela Sánchez, Esteban Garriga, José Núñez

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License